Navigation Links
Anthera Announces the Advancement of Blisibimod into Phase 3 Development for Patients with Systemic Lupus Erythematosus (SLE)
Date:9/17/2012

is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation and autoimmune diseases.

Safe Harbor Statement

Any statements contained in this press release that refer to future events or other non-historical matters, including statements that are preceded by, followed by, or that include such words as "estimate," "intend," "anticipate," "believe," "plan," "goal," "expect," "project," or similar statements, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on Anthera's expectations as of the date of this press release and are subject to certain risks and uncertainties that could cause actual results to differ materially as set forth in Anthera's public filings with the SEC, including Anthera's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the quarter ended June 30, 2012.  Anthera disclaims any intent or obligation to update any forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law.

CONTACT: Bianca Nery of Anthera Pharmaceuticals, Inc., bnery@anthera.com or 510.856.5586.


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Anthera Pharmaceuticals Reports 2012 Second Quarter Financial Results And Provides Clinical Progress Update
2. Anthera Pharmaceuticals Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Common Stock
3. Anthera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
4. Anthera Pharmaceuticals Announces Proposed Public Offering of Common Stock
5. Anthera Pharmaceuticals Provides Additional Data from the Recently Completed PEARL-SC Study of Blisibimod in the Proposed Phase 3 Population
6. Anthera Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
7. Anthera Updates Phase 3 Plans Following Results from the Phase 2b PEARL-SC Dose Ranging Study of Blisibimod
8. Anthera Pharmaceuticals Reports 2012 First Quarter Financial Results And Provides Clinical Progress Update
9. Anthera Announces First Quarter 2012 Financial Report and Conference Call
10. Anthera Announces the Completion of Patient Dosing in Phase 2b PEARL-SC Study
11. Merz, Inc. Announces Cynthia Schwalm as Vice President, Neurology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... Health today reported fourth-quarter fiscal year 2015 revenues ... and non-GAAP diluted earnings per share (EPS) from ... percent. Non-GAAP operating earnings increased 33 percent to ... increased 44 percent to $558 million, and diluted ... $0.88. Fiscal year 2015 revenues increased ...
(Date:7/30/2015)... Ind., July 30, 2015 , Net Sales ... the prior year period and an increase of 5.7% constant ... second quarter was $(0.91), and adjusted earnings per share were ... , Company updates guidance Zimmer Biomet ... for the quarter ended June 30, 2015.  The Company reported ...
(Date:7/29/2015)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) today ... Test v2 for Premarket Approval (PMA) to the ... companion diagnostic test for AZD9291, an AstraZeneca investigational ... an acquired resistant mutation.  Patients ... with tumor containing an EGFR sensitizing mutation show ...
Breaking Medicine Technology:Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 2Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 3Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 4Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 5Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 6Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 7Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 8Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 9Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 10Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 11Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 12Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 13Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 14Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 15Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 16Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 17Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 18Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 19Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 20Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 21Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 22Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 23Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 24Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 25Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 26Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 27Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 28Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 29Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 30Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 31Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 32Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 33Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 34Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 35Cardinal Health Reports Strong Q4 And Record Fiscal Year-End Non-GAAP Operating Earnings Results 36
... Minn., Nov. 17, 2010 People who are searching ... with less potential for flushing can turn to Slo-Niacin®. ... Slo-Niacin® is a niacin supplement that has been shown ... "Slo-Niacin® features a unique patented polygel® system ...
... Sutro Biopharma today announced that the company has ... financing will support the company,s ongoing development of ... the company,s biochemical protein synthesis platform to meet ... Led by Skyline Ventures, the financing round, ...
Cached Medicine Technology:Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 2Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 3Slo-Niacin® Dietary Supplement Shown to Support 'Good' Cholesterol (HDL) 4Sutro Biopharma Secures $36.5 Million in Series C Financing 2
(Date:7/30/2015)... ... July 30, 2015 , ... Western University of Health Sciences faculty, students and ... Games, the largest sports and humanitarian event in the world this year and the ... Games, held July 25 through August 2, 2015, benefited from the participation of WesternU’s ...
(Date:7/30/2015)... Wisconsin (PRWEB) , ... July 30, 2015 , ... Quintessa ... Kybella is a nonsurgical treatment designed specifically for the elimination of ... one of the first locations in the state of Wisconsin to offer this innovative ...
(Date:7/30/2015)... ... July 30, 2015 , ... The New ... the New Jersey Department of Health, has received a $2.9 million grant from ... the U.S. Department of Health and Human Services (HHS). NJII will help the ...
(Date:7/30/2015)... ... ... Bird B Gone, the leader in bird control products for commercial, industrial and ... from the AC units and ventilation systems on hospital roofs. Bird droppings can carry ... virus. When these droppings dry, the fine powder can be carried into hospitals via ...
(Date:7/30/2015)... ... ... After conducting a nationwide executive search led by healthcare leadership solutions firm ... N.Y., has hired Gerard (Jerry) Walsh as Chief Executive Officer. Walsh assumed his new ... Walsh is an expert in organizational change, physician development, implementation of quality and patient ...
Breaking Medicine News(10 mins):Health News:WesternU Makes Big Impact at Special Olympics 2Health News:WesternU Makes Big Impact at Special Olympics 3Health News:Quintessa MedSpa Offers Nonsurgical Double-chin Elimination 2Health News:New Jersey Innovation Institute Awarded $2.9 Million Federal Grant to Advance Health Information Technology Services to Support Health Information Exchange 2Health News:Bird B Gone’s New Bird Hazing System Keeps Disease-Carrying Bird Droppings Out of Hospitals 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 2Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 3Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 4Health News:St. John’s Episcopal Hospital Hires New Chief Executive Officer 5
... sometimes a barrier for patients when it comes to ... barrier increases the risk that a patient will use ... suffer an adverse drug event. , , ScriptPro ... instructions and drug auxiliary warnings, and print them on ...
... receptors was shown to double survival time in mice, according ... phase animal model study were reported in the June 15 ... Care Medicine . Changes in genes encoding nicotine ... smoke, but with susceptibility to lung cancer. Nicotine exposure also ...
... issued today, the nonpartisan watchdog group Public Campaign Action Fund ... health care reform as "hazardous to America,s health, and a ... working families and small business owners in Kentucky." , ... Sen. McConnell,s opposition to health care legislation that includes a ...
... , Additional Group of Compounds and Enhanced Research Activities ... 8 Senetek PLC (OTC Bulletin Board: SNKTY), a ... technologies that target the science of healthy aging, announced ... agreement with the Czech Republic Institute of Experimental Botany ...
... Health Alliance Design Guidelines , , SAN RAMON, ... Alliance announced today that the Continua Health Alliance has ... local area network (LAN) standard. ZigBee Health Care offers ... single network. Continua recommends ZigBee for sensing and control ...
... Solution to Help Employees Lose Weight, Be Healthy and Save Money ... NTRI ), a leading provider of weight management products ... Nutrisystem Works(TM) program to companies and health plans across ... costs. The obesity epidemic continues to rise and studies have ...
Cached Medicine News:Health News:Robot Speaks Many Languages - Improves Pharmacy Patient Outcomes 2Health News:Defeating nicotine's double role in lung cancer 2Health News:Defeating nicotine's double role in lung cancer 3Health News:Watchdog Group Blasts McConnell for Putting Insurance Donors Before Health Care Reform 2Health News:Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 2Health News:Senetek PLC Gains Six Year Extension of Rights from Czech Republic Institute of Experimental Botany 3Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 2Health News:ZigBee Selected by Continua Health Alliance for Next Generation Guidelines 3Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 2Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 3Health News:New Nutrisystem Works(TM) Offers Corporate America New Weapon in the Fight Against Obesity 4